Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Theravance Seen Luring Glaxo Bid as Drugs Near FDA Nod: Real M&A
Bloomberg
Monday, March 25, 2013 - 11:07am
tags:
GSK, Theravance, M&A
FDA Denies Approval For Glaxo Bird Flu Vaccine
Pharmalot
Monday, March 25, 2013 - 11:06am
tags:
FDA, GSK, bird flu, vaccines, Q-Pan H5N1
Sanofi to Seek More Venture-Capital Deals
Bloomberg
Monday, March 25, 2013 - 11:05am
tags:
Sanofi, venture capital, Warp Drive Bio
FDA rejects United Therapeutics' oral hypertension drug again
Reuters
Monday, March 25, 2013 - 11:03am
tags:
antihypertensives, FDA, United Therapeutics, Treprostinil
Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind
Seeking Alpha
Monday, March 25, 2013 - 11:00am
tags:
patent cliff, M&A, Teva, Pfizer, Novartis, GSK, Dendreon, AstraZeneca, Advaxis
Pfizer says XELJANZ approved in Japan for treatment of adults with RA
Yahoo/Fly on the Wall
Monday, March 25, 2013 - 10:59am
tags:
Pfizer, Xeljanz, rheumatoid arthritis, Japan
Actavis reaches agreement with AstraZeneca to launch generic Crestor in 2016
Yahoo/Fly on the Wall
Monday, March 25, 2013 - 10:57am
tags:
generics, Crestor, Actavis, AstraZeneca
Supreme Court: Can drug companies pay to delay generics?
Yahoo/AP
Monday, March 25, 2013 - 10:57am
tags:
pay-for-delay, generics, Supreme Court
2 Can't-Miss FDA Rulings Next Week
Motley Fool
Sunday, March 24, 2013 - 12:27pm
tags:
JNJ, Invokana, type 2 diabetes, diabetes, pulmonary arterial hypertension, Treprostinil
Is Eli Lilly's Management Charting the Right Course?
Motley Fool
Sunday, March 24, 2013 - 12:24pm
tags:
Eli Lilly
Has Horizon Pharma's Share Price Bottomed Out?
Seeking Alpha
Sunday, March 24, 2013 - 12:23pm
tags:
Horizon Phamra
China Biotech In Review: Roche Steps Up As A Bidder For Life Technologies
Seeking Alpha
Sunday, March 24, 2013 - 12:22pm
tags:
BGI, Life Technologies, Roche Holding AG, Simcere, OriGene Technologies, H3 Biomedicine, Eli Lilly, Taiwan Liposome Company, Amoy Diagnostics, Antisense Therapeutics
Is Obamacare a Disaster Waiting to Happen for Big Pharma?
Motley Fool
Sunday, March 24, 2013 - 12:19pm
tags:
Obamacare
Can Johnson & Johnson Turn Around This Lagging Business?
Motley Fool
Sunday, March 24, 2013 - 12:18pm
tags:
JNJ
3SBio Inc. Announces Extraordinary General Meeting of Shareholders
Yahoo/PR Newswire
Sunday, March 24, 2013 - 12:15pm
tags:
3SBio, M&A
3 Humongous Health-Care Stocks This Week
Motley Fool
Sunday, March 24, 2013 - 12:11pm
tags:
Anacor, Obagi Medical Products, Acadia
Takeda seeks Japanese approval for brentuximab vedotin to treat relapsed/refractory CD30 positive HL and ALCL
Pharmabiz
Saturday, March 23, 2013 - 10:15am
tags:
Takeda, brentuximab vedotin, systemic anaplastic large cell lymphoma
4 Pharmaceutical Stocks to Buy Now
InvestorPlace
Saturday, March 23, 2013 - 10:06am
tags:
Repros Therapeutics, JNJ, Bristol-Myers Squibb, Watson Pharmaceuticals
Orphan Drug Is Headed Back to Its Parent: NPS Pharmaceuticals, Inc.
Insider Monkey
Saturday, March 23, 2013 - 10:05am
tags:
NPS Pharmaceuticals, revestive, preotact
Valeant Pharmaceuticals Receives “Buy” Rating from Jefferies Group (VRX)
Zolmax
Saturday, March 23, 2013 - 10:01am
tags:
Valeant Pharmaceuticals

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.